Chronic Fatigue Limits Quality of Life in Imatinib-Treated CML Patients

Blast crisis of CML: Peripheral blood smear revealing the histopathologic features indicative of a blast crisis in the case of CML
HRQOL has become substantially more important in the treatment of CML, as 5-year survival rates have climbed dramatically with the use of tyrosine kinase inhibitors, such as imatinib. Factors associated with HRQOL, though, have not been clearly studied. “Such information would have important clinical implications, for example, to lay the groundwork for developing targeted supportive care programs for CML survivors,” wrote study authors led by Fabio Efficace, PhD, of the Italian Group for Adult Hematologic Diseases in Rome. The new study was published online ahead of print on March 15 in Leukemia.

read full article here:
http://www.cancernetwork.com/chronic-myeloid-leukemia/content/article/10...